Immix Biopharma, Inc.
11400 West Olympic Blvd., Suite 200
Los Angeles, CA 90064
January 9, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Lauren Hamill
| Re: | Immix Biopharma, Inc. | |
| Registration Statement on Form S-3 | ||
| File No. 333-269100 | ||
| Filed January 3, 2023 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Immix Biopharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on Wednesday, January 11, 2023, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Please notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
| Very truly yours, | ||
| IMMIX BIOPHARMA, INC. | ||
| By: | /s/ Ilya Rachman | |
| Name: | Ilya Rachman | |
| Title: | CEO | |
| cc: | Jeffrey Fessler, Sheppard Mullin Richter & Hampton LLP |